Wednesday, June 3, 2020

Investor Ideas #Potcasts, #Cannabis News and #Stocks on the Move; Episode 422 (OTC: $CSUI) (NASDAQ: $HUGE) (TSX: $RIV.TO) (OTCQB: $CBDY) (TSX: $HEXO.TO) (OTC: $CURR)

Investor Ideas #Potcasts, #Cannabis News and #Stocks on the Move; Episode 422 (OTC: $CSUI) (NASDAQ: $HUGE) (TSX: $RIV.TO) (OTCQB: $CBDY) (TSX: $HEXO.TO) (OTC: $CURR)

Delta, Kelowna, BC, June 3, 2020 ( Newswire), a global news source covering leading sectors including marijuana and hemp stocks and its potcast site,  release today’s podcast edition of  cannabis news and stocks to watch plus insight from thought leaders and experts.

Listen to the podcast:

Today’s podcast overview/transcript:

Good afternoon and welcome to another episode of "Potcast" featuring cannabis news, stocks to watch as well as insights from thought leaders and experts.

Today’s podcast is sponsored by Cannabis Suisse Corp. (OTC: CSUI)a research & development company licensed under Swiss Cannabis and tobacco regulations to cultivate and sell cannabis. The Company's facilities for producing cannabis are based in Zurich.

The Company grows high quality, organic cannabis with sustainable, all-natural principles. Cannabis Suisse products are laboratory tested to ensure the end users have access to a standardized, safe and consistent product.

In today’s podcast we will be looking at a few public company announcements.

FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) had a “huge” run today, up nearly 180%, after having announced that the U.S. Food and Drug Administration (FDA) has given the company permission to submit an Investigational New Drug Application (IND) for the use of FSD-201 (ultramicronized palmitoylethanolamide, or ultramicronized PEA)  to treat COVID-19, the disease caused by the SARS-CoV-2 virus. Severe COVID-19 is characterized by an over-exuberant inflammatory response that may lead to a cytokine storm and ultimately death. FSD Pharma is focused on developing FSD-201 for its anti-inflammatory properties to avoid the cytokine storm associated with acute lung injury in hospitalized COVID-19 patients.

"FDA's permission to design a proof-of-concept study in COVID-19 patients evaluating clinical doses of FSD-201 is a paradigm shift for FSD Pharma and is the result of outstanding work conducted by Dr. Edward Brennan, President FSD BioSciences, and his team," said Raza Bokhari, MD, Executive Co-Chairman & CEO. "We contacted the FDA in late-March 2020 after becoming aware that several Italian physicians and scientists were advocating for use of ultramicronized PEA for patients suffering from symptoms of COVID-19, based on the drug's mechanism of action as a potent and safe anti-inflammatory agent that reduces the production of pro-inflammatory cytokines. Numerous studies over the past 40 years also validate the efficacy and safety of ultramicronized PEA in the treatment and prophylactic effects in respiratory infections. These studies also pointed out that the ease of application of PEA offers the possibility to have a quick therapeutic answer ready in case of a flu epidemic."

Based on the FDA feedback received to date, we expect the trial will be a randomized, controlled, double-blind, U.S. multicenter study to assess the efficacy and safety of FSD-201 dosed 600mg or 1200mg twice-daily plus standard of care (SOC) versus SOC alone in symptomatic patients with clinical presentation compatible with COVID-19. Eligible patients will present with symptoms consistent with influenza/coronavirus signs (fever, dry cough, malaise, difficulty breathing) and/or newly documented positive COVID-19 disease.

The primary endpoint is to determine if FSD-201 plus SOC provides a significant improvement in clinical status (i.e., shorter time to symptom relief). Key secondary objectives include determining if FSD-201 plus SOC demonstrates additional benefit in terms of safety, objective assessments such as length of time to normalization of fever, length of time to improvement of oxygen saturation and length of time to clinical progression including time to mechanical ventilation or hospitalization, and length of hospital stay. The exploratory endpoint is cytokine clearance as measured by Enzyme Linked Immunosorbent Assay (ELISA).

The treatment period is expected to be 14 days.  All patients who experience clinical benefit are expected to continue to receive their assigned treatment until study completion.

Canopy Rivers Inc. (TSX: RIV) (OTC: CNPOF), a venture capital firm specializing in cannabis, today released its audited consolidated financial statements for the fiscal year ended March 31, 2020 and management's discussion and analysis for the three and twelve months ended March 31, 2020.

"The global economic uncertainty brought on by COVID-19 capped off a volatile and challenging year for the cannabis sector. Despite these challenges, I am pleased with what our team achieved last year. However, we were not immune to this volatility, and following a strategic and operational review of our business, we recently announced a number of changes aimed at strengthening our financial discipline and positioning Canopy Rivers for sustained success moving forward," said NarbĂ© Alexandrian, President and CEO of Canopy Rivers. "Reflecting on the past year, there were several significant achievements that make me optimistic for fiscal year 2021. First, our portfolio companies reached new milestones, including the licensing of PharmHouse, the expansion of TerrAscend's U.S. operations, and ZeaKal's successful trials of its PhotoSeed™ technology. Second, our graduation to the TSX and the launch of our Strategic Advisory Board signalled our company's continued maturation. Finally, we made four new investments, including two in ag-tech, which we believe is a critical component of the value chain that is poised to disrupt the cannabis sector."

"While headwinds persist, we remain positive as we evaluate new opportunities that we believe will ultimately create value for our shareholders and help build the cannabis industry of tomorrow," added Alexandrian.

"Looking back on FY 2020, it is clear that cannabis companies encountered challenging conditions in the capital markets over those 12 months, and the impact of this shows in our financial results for the fiscal year," said Eddie Lucarelli, CFO of Canopy Rivers. "However, we believe that this is more of a function of the slower-than-expected pace of development of the cannabis economy, rather than its long-term potential, which we continue to believe is significant. Based on our available cash resources and deep sector insights, we believe we are well-positioned to capitalize on the current market conditions and strengthen our portfolio of cannabis disruptors."

TARGET GROUP INC. (OTCQB: CBDYannounced that its wholly owned subsidiary, Canary RX Inc. has entered into an agreement to form a Joint Venture Partnership with THRIVE CANNABIS INC. in Norfolk County, ON for the production of premium craft cannabis.

The terms of the 5 year definitive agreement have Target and Thrive each with a 50% ownership of the JV. Target, via its wholly owned subsidiary Canary RX Inc. will permit Thrive to produce premium craft grown cannabis in 7 of its 8, 2300 square foot growing rooms within its existing 44,000 sq. ft. licenced cultivation facility in Norfolk County, ON. In addition, Thrive will maintain and supervise the staff on their proprietary methods of cultivation that it currently utilizes from its production in Canada. Operations within the facility are expected to begin immediately.

This partnership is anticipated to increase the initial production yields within the Canary RX facility and will encompass stronger cultivation management led by an already proven team. Once operational, the JV will begin producing premium craft cannabis for both Target and Thrive, to supply existing distribution networks in Canada. The JV will, additionally, utilize formulations from both parties in Canada as well as manufacture proprietary branded products that both parties plan to distribute throughout their respective supply chains.

"Moving forward with Thrive Cannabis in the form of this JV allows us to execute our growth strategy more quickly and efficiently. Their knowledge in maximising the growth of cannabis in our Canary Rx facility and development of genetics is next to none. We are very excited with the Thrive partnership and experience their team brings" said Tony Zarcone, Target Group's CEO.

"This is a world class asset to take on under our management that adds substantial capacity for the cultivation of premium indoor flower. We could not be happier to be partnering with Canary RX for the mutual benefit of our organizations and shareholders," said Geoff Hoover, Thrive CEO.

The JV will also look to manufacture white label products for other licensed producers throughout Canada, and it is currently in talks with several potential customers to produce other value-added cannabis products such as tinctures, topicals, pre-rolls, food products and formulated bulk THC/CBD oil.

HEXO Corp (TSX: HEXO) (NYSE: HEXOannounced the launch of a new 30 gram medical flower format for its popular high-THC strain Tsunami under HEXO medical cannabis.

HEXO has been dedicated to providing Canadian clients high quality medical cannabis since 2015. A year ago, the Company updated its medical packaging to comply with the Cannabis Regulations, resulting in smaller product formats.  HEXO is proud to launch a new 30 g format offered in a resealable, odour-proof and child-resistant pouch.

“We know our medical clients have been waiting for this opportunity to purchase a higher volume of cannabis without excess packaging,” said HEXO CEO and co-founder Sebastien St-Louis. "Our Tsunami flower benefits from enhanced humidity controls for maximum freshness and to promote ideal bud density.”

The move to a larger format and a new type of packaging is an important step on HEXO’s sustainability journey and provides medical clients with a more discreet option for high volume orders.

“At HEXO, we have a long history of medical cannabis. We offer our clients free shipping and absorb the federal excise tax on their behalf,” added St-Louis. “This product is being offered exclusively to medical clients and we look forward to continuing to roll out additional strains in this format soon.”

CURE Pharmaceutical (OTC: CURR), an innovative drug delivery and development company, announced today a collaboration with PMI, a subsidiary of Factoria Bogar in Guadalajara, Mexico. PMI will have access to CURE’s innovative drug delivery platform, CUREform™ for its drug formulation, as well as become its distribution partner in Mexico for CURE’s wellness products, such as its vitamin D supplement, sleep and CBD combination products.

“This collaboration enables us to reach new markets with our suite of wellness products as well as prompt innovation with new drug formulations and conduct valuable patient studies on drug efficacy,” said Rob Davidson, CEO of CURE. “This is a valuable partnership from both a revenue perspective as well as an opportunity to expand product offerings and research collaborations.”

PMI will be distributing CURE’s wellness products throughout Mexico, including its weekly vitamin D supplement and sleep aid delivered using CUREfilm® technology. The weekly vitamin D supplements provides 50,000 IU of vitamin D3 to reduce risk of infections. CURE sleep strips contain a soothing blend of melatonin, naturally occurring amino acids and beneficial vitamins that promote fast-acting, balanced sleep patterns for a deep, restful slumber and a rejuvenated awakening.

“Staying healthy and getting enough sleep are at the top of everyone’s mind during these very stressful days and CURE’s wellness products are welcome addition to our offerings,” said Mauricio Villanueva, CEO of PMI and Factoria Bogar. “Incorporating CURE’s drug delivery platform into our future drug and wellness formulations will create new opportunities to differentiate ourselves in the market.”

The PMI collaboration will include several development initiatives with its proprietary prebiotic product from Agave in combination with CBD that leverages the CUREform™ novel delivery platform for treatment of multiple GI indications. With CUREform, the delivery of cannabinoids is easier and more effective because it offers increased bioavailability, simple precision of dosing and greater palatability. There are patient studies planned for Mexico to improve drug efficacy with CBD and prebiotics.

Once again, today’s podcast was sponsored by Cannabis Suisse Corp. (OTC: CSUI)a research & development company licensed under Swiss Cannabis and tobacco regulations to cultivate and sell cannabis. The Company's facilities for producing cannabis are based in Zurich.
The Company grows high quality, organic cannabis with sustainable, all-natural principles. Cannabis Suisse products are laboratory tested to ensure the end users have access to a standardized, safe and consistent product.
Investor ideas reminds all listeners to read our disclaimers and disclosures on the website and this podcast is not an
ucts or services or securities. Investors are reminded all investment involves risk and possible loss of investment   

Learn more about our cannabis podcasts at

To hear more podcasts visit: podcasts are also available on iTunes,  Spotify, Google Play Music, Stitcher, Spreaker,   YouTube via Spreaker,  iHeartradio and Tunein.

Potcasts is now a certified word mark Trademark on the blockchain through Cognate, Inc. CM Certification-Registration Number: 10468217708

About - News that Inspires Big Investing Ideas is a recognized news source publishing third party news, research and original financial content. Learn about investing in stocks and sector trends with our news alerts, articles, podcasts and videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy and more. Investor Idea’s original branded content includes the following podcasts and columns : Crypto Corner , Play by Play sports and stock news column, Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast and column,  Cleantech and Climate Change , Exploring Mining  the AI Eye .
Disclaimer/Disclosure: is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. Disclosure: CSUI is a paid news and social media client
More disclaimer info: Learn more about publishing your news release and our other news services on the newswire and Global investors must adhere to regulations of each country. Please read privacy policy:

Investor Ideas does not condone the use of cannabis except where permissible by law. Our site does not possess, distribute, or sell cannabis products.

Download our Mobile App for iPhone and Android 

800 665 0411

Get more Cannabis Stock Investor Ideas – news, articles, podcasts and stock directory

No comments:

Post a Comment